Press coverage about Veru (NASDAQ:VERU) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Veru earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.1276852834417 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Veru (VERU) opened at $1.24 on Tuesday. The company has a market cap of $65.98, a PE ratio of -6.53 and a beta of 1.24. Veru has a 1-year low of $0.90 and a 1-year high of $3.00.
Several research firms recently weighed in on VERU. HC Wainwright set a $5.00 price target on shares of Veru and gave the stock a “buy” rating in a research report on Thursday, December 14th. ValuEngine upgraded shares of Veru from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Finally, Zacks Investment Research upgraded shares of Veru from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a research report on Wednesday, September 27th.
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.